RxDoctor Payments Data

John Webb, MD

Neurology · Crestview Hills, KYNPI 1891762563

Payments from drug & device makers

$4,516in general payments, 2019–2025

Across 224 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$577
  • AbbVie$558
  • Lilly USA, LLC$347
  • Teva Pharmaceuticals USA, Inc.$238
  • AstraZeneca$231
  • Amneal Pharmaceuticals LLC$216
  • plus $2K from 37 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$4,35496%
  • Education$1423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,516 in reported general payments places this provider in the 55th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$107,787
Medicare patients
422
Services billed
4,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate13$120,670
GlatopaGlatiramer Acetate13$34,944
Aimovig AutoinjectorErenumab-Aooe22$20,090
Emgality PenGalcanezumab-Gnlm24$17,289
NuedextaDextromethorphan Hbr/Quinidine12$16,702
Nurtec OdtRimegepant Sulfate14$15,610
EliquisApixaban17$11,143
NamzaricMemantine Hcl/Donepezil Hcl13$7,325
Levetiracetam212$7,262
Carbidopa-LevodopaCarbidopa/Levodopa193$6,170
Carbamazepine ErCarbamazepine24$5,567
Memantine Hcl ErMemantine Hcl14$5,275
Dimethyl Fumarate26$4,496
Lacosamide51$4,387
Gabapentin340$4,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$577$120,67013 claims
PfizerNurtec Odt, Eliquis, Dilantin$108$29,81944 claims
AbbVieNamzaric$558$7,32513 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$216$3,02733 claims
Upsher-smith Laboratories LLCTopiramate$25$1,452110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 210 neurology providers in Kentucky.

Other neurology in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →